@article{ATM8611,
author = {Alejandro Santos-Lozano and Diana Villamandos García and Fabian Sanchis-Gomar and Carmen Fiuza-Luces and Helios Pareja-Galeano and Nuria Garatachea and Gisela Nogales Gadea and Alejandro Lucia},
title = {Niemann-Pick disease treatment: a systematic review of clinical trials},
journal = {Annals of Translational Medicine},
volume = {3},
number = {22},
year = {2015},
keywords = {},
abstract = {The aim of this systematic review was to analyse all the published clinical trials assessing treatments for Niemann-Pick (NP) disease. At present there are only trials investigating the treatment of NP disease type C. Furthermore, there is no uniformity among studies in treatment outcomes or in data analysis and presentation of results. Miglustat is able to delay neurodegeneration, with greater benefits in patients with a late onset of the disease and β-cyclodextrin-hydroxypropyl (HBP-CD) can attenuate clinical symptoms. As for cholesterol-lowering drugs, the combination of lovastatin, cholestyramine and nicotinic acid is the most effective one for lowering cholesterolemia. Further research is much needed, and ongoing trials using enzyme replacement therapy might hopefully show promising results in the foreseeable future.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/8611}
}